Esperion Therapeutics | ESPR - Los Gastos Financieros De La Deuda





Los Gastos Financieros De La Deuda Cambio Fecha
AbbVie USD 645M 69M 2026-03
Alnylam Pharmaceuticals USD 69.29M 60.05M 2026-03
Amarin USD 3K 5K 2024-12
Amgen USD 657M 4M 2026-03
Biogen USD 72.6M 12.6M 2025-06
BioMarin Pharmaceutical USD 14.96M 12.18M 2026-03
Cipla INR 131.3M 9M 2026-03
CSL USD 215M 111M 2025-12
Cytokinetics USD 33.34M 3M 2026-03
Daiichi Sankyo JPY 2.16B 1.33B 2025-12
Eli Lilly USD 114.7M 134.3M 2025-09
Esperion Therapeutics USD 22.64M 585K 2025-12
Geron USD 7.15M 150K 2026-03
Grifols EUR 156.07M 31.46M 2025-09
Halozyme Therapeutics USD 5.51M 597K 2026-03
Heron Therapeutics USD 600K 100K 2024-12
Ionis Pharmaceuticals USD 17M 1000K 2026-03
Merck USD 479M 67M 2026-03
Minerva Neurosciences USD 2.31M 60K 2024-06
Moderna USD 11.49B 36B 2026-03
Nektar Therapeutics USD 9.77M 3.75M 2025-12
Pfizer USD 671M 40M 2026-03
PTC Therapeutics USD 2.87B 2.82B 2026-03
Puma Biotechnology USD 3.37M 11K 2024-06
Regeneron Pharmaceuticals USD 12.9M 700K 2026-03
Sanofi EUR 178M 203M 2026-03
Sarepta Therapeutics USD 20.84M 13.28M 2025-12
United Therapeutics USD 3.1M 100K 2025-12
Vanda Pharmaceuticals -1.37B 1.97B 2025-12